CYCLERION THERAPEUTICS INC - COMMON STOCK (CYCN)
CUSIP: 23255M105
Q4 2022 13F Holders as of 31 Dec 2022
- Type / Class
- Equity / COMMON STOCK
- Shares outstanding
- 4,330,313
- Total 13F shares
- 20,827,653
- Share change
- -409,108
- Total reported value
- $13,665,576
- Put/Call ratio
- 0.6%
- Price per share
- $0.66
- Number of holders
- 36
- Value change
- -$347,030
- Number of buys
- 19
- Number of sells
- 12
Quarterly Holders Quick Answers
What is CUSIP 23255M105?
CUSIP 23255M105 identifies CYCN - CYCLERION THERAPEUTICS INC - COMMON STOCK in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 23255M105:
Top shareholders of CYCN - CYCLERION THERAPEUTICS INC - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Slate Path Capital LP |
13F
|
Company |
165%
|
7,157,601
|
$6,156,000 | — | 30 Sep 2022 | |
| FMR LLC |
13F
|
Company |
79%
|
3,413,860
|
$2,936,000 | — | 30 Sep 2022 | |
| MFN Partners Management, LP |
13F
|
Company |
78%
|
3,389,215
|
$2,915,000 | — | 30 Sep 2022 | |
| Artal Group S.A. |
13F
|
Company |
64%
|
2,779,122
|
$2,391,000 | — | 30 Sep 2022 | |
| VANGUARD GROUP INC |
13F
|
Company |
38%
|
1,650,704
|
$1,419,000 | — | 30 Sep 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
13%
|
583,819
|
$502,000 | — | 30 Sep 2022 | |
| BlackRock Finance, Inc. |
13F
|
Company |
8.3%
|
360,660
|
$310,000 | — | 30 Sep 2022 | |
| TRUSTCORE FINANCIAL SERVICES, LLC |
13F
|
Company |
6.8%
|
292,645
|
$252,000 | — | 30 Sep 2022 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
6.5%
|
283,388
|
$244,000 | — | 30 Sep 2022 | |
| Diametric Capital, LP |
13F
|
Company |
5.6%
|
243,711
|
$210,000 | — | 30 Sep 2022 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
5.4%
|
231,952
|
$198,000 | — | 30 Sep 2022 | |
| STATE STREET CORP |
13F
|
Company |
2.7%
|
115,414
|
$99,000 | — | 30 Sep 2022 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.7%
|
115,000
|
$99,000 | — | 30 Sep 2022 | |
| COLONY GROUP LLC |
13F
|
Company |
2.4%
|
102,884
|
$88,000 | — | 30 Sep 2022 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.1%
|
92,541
|
$80,000 | — | 30 Sep 2022 | |
| NORTHERN TRUST CORP |
13F
|
Company |
1.9%
|
80,736
|
$69,000 | — | 30 Sep 2022 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1.8%
|
78,919
|
$68,000 | — | 30 Sep 2022 | |
| Intrinsic Value Partners, LLC |
13F
|
Company |
1.1%
|
48,315
|
$42,000 | — | 30 Sep 2022 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1%
|
45,339
|
$39,000 | — | 30 Sep 2022 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.85%
|
36,600
|
$31,000 | — | 30 Sep 2022 | |
| MACKENZIE FINANCIAL CORP |
13F
|
Company |
0.63%
|
27,320
|
$23,000 | — | 30 Sep 2022 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.62%
|
26,801
|
$23,000 | — | 30 Sep 2022 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.47%
|
20,230
|
$17,000 | — | 30 Sep 2022 | |
| Verition Fund Management LLC |
13F
|
Company |
0.46%
|
20,000
|
$17,000 | — | 30 Sep 2022 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.41%
|
17,968
|
$15,000 | — | 30 Sep 2022 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.24%
|
10,314
|
$9,000 | — | 30 Sep 2022 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.21%
|
9,043
|
$8,000 | — | 30 Sep 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0.08%
|
3,255
|
$3,000 | — | 30 Sep 2022 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.01%
|
317
|
$273 | — | 30 Sep 2022 | |
| Andreas Busch |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
135,000
|
— | — | 20 Jan 2022 | |
| Anjeza Gjino |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
135,000
|
— | — | 20 Jan 2022 | |
| Cheryl Gault |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
135,000
|
— | — | 20 Jan 2022 | |
| George H. Conrades |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Marsha Fanucci |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Michael Mendelsohn |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Ole Isacson |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Stephanie Lovell |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Kevin Churchwell |
3/4/5
|
Director |
—
class O/S missing
|
10,000
|
— | — | 24 Jun 2021 |
Institutional Holders of CYCLERION THERAPEUTICS INC - COMMON STOCK (CYCN) as of Q4 2022
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2022 vs Q3 2022 Across Filers
| Investor | Q3 2022 Shares | Q4 2022 Shares | Share Diff | Share Chg % | Q3 2022 Value $ | Q4 2022 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.